ACO

ACO is a Swedish skincare brand founded in 1939 by Apotekarsocieteten, the Swedish Pharmaceutical Society, at Wallingatan 26 in central Stockholm [1][2]. Created as the society's own label to assure the quality of pharmacy-made skincare and self-care products, it takes its name from "Apotekens Composita", Latin for the pharmacy's blend or mixture [2]. The brand has built its identity around products developed in its own Stockholm laboratory and validated by clinical and safety documentation, and by 2022 it was described in trade coverage as Sweden's best-selling pharmacy skincare brand, citing IQVIA sales data [16].

The company remains active. After more than eight decades inside the Swedish pharmacy channel, ACO began expanding into mainstream retail in 2025 and changed corporate ownership in 2026, when it passed to the Stockholm-based group Karo Healthcare. Its range spans facial skincare, body care, sun protection, hair care and medicated products for dry skin and eczema.

ACO emerged from the pharmacy profession rather than the cosmetics industry. Apotekarsocieteten, the Swedish Pharmaceutical Society, established the brand in 1939 as a collective label so that skincare and self-care products made within pharmacies met a consistent standard. The name condenses that origin: "Apotekens Composita" describes a pharmacy's prepared mixture.

Sources record two closely spaced founding dates. ACO's own history places the launch in 1939, the year used in its long-running tagline "Hudvårdsprodukter sedan 1939" (skincare products since 1939) [1]. Apotekarsocieteten's institutional history instead dates the establishment of the ACO trademark to 1940, framing it as a way to guarantee the quality of pharmacy-produced medicines [19]. The two dates mark different steps — brand launch and formal trademark registration — in the same founding process.

Through the 1980s, ACO gained shelf presence with distinctive packaging, and in 1988 it introduced several products including ACO Bronze, a roll-on deodorant for men and a moisture lotion. A defining moment came in 1998 with Canoderm, a urea cream launched together with research on the prevention of atopic eczema recurrence; the product became one of the brand's most prominent lines.

Over the following decades ACO settled into the position of Sweden's leading pharmacy skincare brand, building a portfolio organised around skin needs and life stages. According to the company, this came to include the Minicare series for babies, the Spotless range for acne-prone skin and Age Delay for mature skin, alongside its core face and body lines. In 2022 it extended beyond the Nordics with a direct-to-consumer launch in the United States, marketed as "Stockholm's Best Kept Skincare Secret". In 2025 it took a further step on its home market, expanding beyond pharmacies for the first time since 1939 by entering the retailers Lyko and Kicks, both in stores and online [2].

For most of its history ACO sat within Apotekarsocieteten's collective branding. The documented record of independent ownership begins in 2003, when the private-equity firm Altor Equity Partners acquired Aco Hud AB in a buyout that Altor records as its first deal in Sweden and its first in life sciences [17]. The following year, in 2004, the Belgian healthcare company Omega Pharma NV bought the business from Altor [18]. ACO then changed hands again in 2015, when Omega Pharma — and with it ACO — was absorbed into the American company Perrigo [9].

In 2026, ownership moved to Karo Healthcare, a KKR-backed consumer-health group headquartered in Stockholm, which acquired ACO from Perrigo as part of a wider dermocosmetics portfolio for around 330 million euros; the deal closed on 30 April 2026 [11]. Karo Healthcare itself emerged from Karo Pharma after KKR took that company private in 2019. As a condition of approval, the Norwegian Competition Authority required Karo Healthcare to divest the Locobase brand in the Nordic countries, citing overlap in the market for medicated skincare [14]. At the time of the source material, ACO's website still carried Perrigo links in its footer for privacy and legal terms, reflecting that the site had not yet been updated after the change of parent [1].

The acquired portfolio, which the seller's parent reported as generating more than 120 million euros in net sales in 2024, groups ACO with sub-brands including Cosmica, Canoderm, Cliniderm and Miniderm. The transaction placed ACO alongside other dermocosmetic names, Biodermal, Emolium and Iwostin, inside Karo Healthcare's skin-health business.

ACO presents itself as a pharmacy-rooted, science-led brand. The company says it works only with ingredients it considers proven safe, and frames quality as the use of few, pure and carefully chosen raw materials with a clear function and without unnecessary additives. It points to roughly eight decades of accumulated knowledge and to formulation in its own Stockholm laboratory as the basis for this approach.

The brand takes an unusually direct line on preservatives. Rather than advertising "free-from" claims, its ingredient guide lists parabens among the ingredients it uses and describes them as safe, well-documented preservatives — a stance that runs counter to the marketing of many competitors. Across its lines ACO positions itself as a dermatologist-tested option for the general pharmacy shopper, with products grouped by skin type and life stage rather than by trend.

ACO's catalogue is organised into a number of named series, among them Protect, Pigment, Age Delay, Spotless and the more recent Purifying line aimed at adult skin prone to blemishes. Formulations draw on widely used skincare ingredients such as glycerin, hyaluronic acid, niacinamide, panthenol, urea and exfoliating acids (AHA and BHA).

The brand's most documented product is Canoderm, a 5% urea cream classified as an over-the-counter medicine for dry skin and the prevention of atopic eczema. ACO describes it as Sweden's most well-documented emollient medicine, citing peer-reviewed clinical studies, and reports that in patients with atopic eczema it produced roughly 47% more eczema-free days than a neutral-effect moisturiser [5]. The company also notes a comparative finding that a competing 5% urea cream weakened the skin barrier while Canoderm reinforced it, which it presents as evidence that a cream's whole composition, not its urea content alone, determines its effect on the barrier. Other lines include the Miniderm family for babies and children and the Repair Cream for compromised skin.

ACO's environmental statements focus on production and packaging. The company says it works to reduce energy use, greenhouse gas emissions, water consumption and waste, and applies three packaging principles: cutting plastic in favour of more sustainable materials, reducing packaging weight, and optimising volume per shipping pallet. Some body-cleansing products are offered in refill packaging, and the brand has partnered with the recycling company Bower to let consumers return used packaging.

The brand's published sustainability material carries no specific eco-certifications and no quantified targets or target years — a notable absence given how common labels such as the Nordic Swan are among Swedish pharmacy brands.

ACO has drawn most of its outside coverage as a business and market story rather than through beauty-press editorial. Its 2022 United States launch was reported in financial and trade outlets, which repeated the brand's standing as Sweden's number-one pharmacy skincare brand by IQVIA-measured sales. Its later change of ownership was covered as part of Karo Healthcare's acquisition of Perrigo's dermocosmetics business and the related Norwegian regulatory decision.

ACO is an active, multi-market brand, described in its source material as a household name across the Nordics and Germany and, since 2022, present in the United States through direct-to-consumer sales. It maintains an active social-media presence under the acosverige handle on Facebook, Instagram and YouTube. Its most recent developments include the 2025 expansion into Swedish retail beyond pharmacies, continued new-product activity such as the Purifying series, and the completion of its acquisition by Karo Healthcare on 30 April 2026.